FR2685870A1 - Medicament anticancereux. - Google Patents

Medicament anticancereux. Download PDF

Info

Publication number
FR2685870A1
FR2685870A1 FR9200016A FR9200016A FR2685870A1 FR 2685870 A1 FR2685870 A1 FR 2685870A1 FR 9200016 A FR9200016 A FR 9200016A FR 9200016 A FR9200016 A FR 9200016A FR 2685870 A1 FR2685870 A1 FR 2685870A1
Authority
FR
France
Prior art keywords
anticancer medicament
active ingredient
excipient
dose
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9200016A
Other languages
English (en)
Other versions
FR2685870B1 (fr
Inventor
Soussan Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9200016A priority Critical patent/FR2685870B1/fr
Publication of FR2685870A1 publication Critical patent/FR2685870A1/fr
Application granted granted Critical
Publication of FR2685870B1 publication Critical patent/FR2685870B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Le principe actif est le virus de l'hépatite A et l'excipient est de l'eau. Le médicament se présente en solution buvable.

Description

MEDICAMENT ANTICANCEREUX
L'invention concerne un médicament anticancéreux.
Selon l'invention, ce médicament comporte comme principe actif le virus de l'hépatite A et comme excipient de 1 l'eau. La dose de principe actif est superieure a 300.000 DICC50. Il est rappelé que l'abréviation DICC50 signifie dose infectieuse à 50% en culture cellulaire sensible. La dose de principe actif du virus de l'hépatite
A pourra etre calculée en fonction d taux des transaminases in vitro, ce taux étant alors pris égal à dix fois le taux normal Le medicament se presente sous forme d u n e solution buvable, susceptible ddetre administrée à jeun. et contenue dans un flacon unidose de 5ml.
La tolérance au médicament a été constatée sur de nombreux cas par centrale du taux desf transaminases q u i reste normal Aucun cas d'hépatite virale de type A nia été constaté

Claims (2)

REVENDICATIONS
1. Médicament anticancereux caractérisé en ce qu'il comporte comme principe actif le virus de l'hépatite A et comme excipient de l'eau.
2. Médicament selon la revendication 1 caractérisé en ce que la a dose de principe actif est superieure à 300.000 DICC50 pour une quantité d'excipient de 5ml
FR9200016A 1992-01-03 1992-01-03 Medicament anticancereux. Expired - Fee Related FR2685870B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9200016A FR2685870B1 (fr) 1992-01-03 1992-01-03 Medicament anticancereux.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9200016A FR2685870B1 (fr) 1992-01-03 1992-01-03 Medicament anticancereux.

Publications (2)

Publication Number Publication Date
FR2685870A1 true FR2685870A1 (fr) 1993-07-09
FR2685870B1 FR2685870B1 (fr) 1995-07-07

Family

ID=9425388

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9200016A Expired - Fee Related FR2685870B1 (fr) 1992-01-03 1992-01-03 Medicament anticancereux.

Country Status (1)

Country Link
FR (1) FR2685870B1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU69412A1 (fr) * 1973-02-19 1974-05-29
FR2278345A2 (fr) * 1974-01-23 1976-02-13 Soussan Andre Medicament antineoplasique
FR2526435A2 (fr) * 1982-05-05 1983-11-10 Soussan Andre Nouvel interferon et procede de preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU69412A1 (fr) * 1973-02-19 1974-05-29
FR2278345A2 (fr) * 1974-01-23 1976-02-13 Soussan Andre Medicament antineoplasique
FR2526435A2 (fr) * 1982-05-05 1983-11-10 Soussan Andre Nouvel interferon et procede de preparation

Also Published As

Publication number Publication date
FR2685870B1 (fr) 1995-07-07

Similar Documents

Publication Publication Date Title
CA2168732A1 (fr) Capsules de gelatine renfermant une solution d'acetaminophene fortement concentree
DK158931C (da) Fremgangsmaade til fremstilling af et retarderet oralt farmaceutisk praeparat indeholdende 5-amino-salicylsyre
GB9907715D0 (en) Pharmaceutical compositions
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
CA2086343A1 (fr) Composition thyroactive a liberation prolongee
IL77186A0 (en) Pharmaceutical insulin composition
OA09023A (fr) Composition pharmaceutique, administrable par voie orale, destinée à réduire les effets des b-lactamines.
FI945452A0 (fi) Ibuprofeenia sisältävä poreileva lääkevalmiste sekä sen valmistusmenetelmä
JPS6413021A (en) Lithium salt-containing pharmacological composition
US5665384A (en) Oily capsules of ketoprofen
DE19975059I2 (de) (2-Oxo-3-tetrahydrothienylcarbamoyl)-alkylthio-essigsäure, ihre Salze und Ester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel.
DK15388A (da) Fremgangsmaade til fremstilling af et forsinkelsesprodukt indeholdende diltiazem med en saerlig daglig dosering
FR2685870A1 (fr) Medicament anticancereux.
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof
JPS5350316A (en) Drug composition for oral administration
NZ502807A (en) Preparation of solid oral dosage forms of alendronic acid (4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid)
FR2659553B1 (fr) Procede de preparation de compositions homeopathiques a partir d'une solution initiale contenant une substance active.
PT86061A (en) Process for the preparation of analgesic pharmaceutical compositions containing a synergic mixture of ibuprofen with tizanidine
JPS55122715A (en) Antidiabetic agent
KR830009776A (ko) 세포 보호 유도방법
JPS57158719A (en) Rectal administration pharmaceutical
JPS5764655A (en) Novel benzoylaminophenylcarboxylic acid derivative, its preparation, and drug composition comprising it
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung

Legal Events

Date Code Title Description
ST Notification of lapse